Introduction：Basic information about CAS 83898-65-1|5-chloro-1-[1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]piperidin-4-yl, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | 5-chloro-1-[1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one maleate |
|---|
| CAS Number | 83898-65-1 | Molecular Weight | 541.98300 |
|---|
| Density | / | Boiling Point | / |
|---|
| Molecular Formula | C26H28ClN5O6 | Melting Point | / |
|---|
| MSDS | / | Flash Point | / |
|---|
Names
| Name | domperidone maleate |
|---|
| Synonym | More Synonyms |
|---|
BiologicalActivity
| Description | Domperidone (R33812) monomaleate is an orally active and selective dopamine-2 receptor antagonist. Domperidone monomaleate acts as an antiemetic and a prokinetic agent through its effects on the chemoreceptor trigger zone and motor function of the stomach and small intestine[1]. |
|---|
| Related Catalog | Signaling Pathways >>GPCR/G Protein >>Dopamine ReceptorSignaling Pathways >>Neuronal Signaling >>Dopamine ReceptorResearch Areas >>Neurological Disease |
|---|
| In Vitro | Cardiac Na+ channels are common targets of therapeutics inducing cardiotoxicity[3]. Domperidone monomaleate (0-1000 μM) displays concentration- and state-dependent inhibitory of Nav1.5 in Human embryonic kidney HEK293 cells[3]. Domperidone monomaleate (0, 10, 100 μM) displays tonic and use-dependent block to Na currents in rat cardiomyocytes with a IC50 of 312 μM[3]. |
|---|
| In Vivo | Unlike Metoclopramide, Domperidone monomaleate does not cause any adverse neurological symptoms as it has minimal penetration through the blood-brain barrier[1]. Domperidone monomaleate acts as both an antiemetic and an upper gastrointestinal tract prokinetic agent. It is rapidly absorbed after oral administration, and few side effects have been reported[2]. |
|---|
| References | [1]. Reddymasu SC, et al. Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol. 2007;102(9):2036-2045. [2]. Champion MC, et al. Domperidone, a new dopamine antagonist. CMAJ. 1986;135(5):457-461. [3]. Stoetzer C, et al. Cardiotoxic Antiemetics Metoclopramide and Domperidone Block Cardiac Voltage-Gated Na+ Channels. Anesth Analg. 2017 Jan. 124(1):52-60. |
|---|
Chemical & Physical Properties
| Molecular Formula | C26H28ClN5O6 |
|---|
| Molecular Weight | 541.98300 |
|---|
| Exact Mass | 541.17300 |
|---|
| PSA | 153.42000 |
|---|
| LogP | 3.00290 |
|---|
| InChIKey | OAUUYDZHCOULIO-BTJKTKAUSA-N |
|---|
| SMILES | O=C(O)C=CC(=O)O.O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1 |
|---|
Safety Information
Customs
Synonyms
| (Z)-but-2-enedioic acid,6-chloro-3-[1-[3-(2-oxo-3H-benzimidazol-1-yl)propyl]piperidin-4-yl]-1H-benzimidazol-2-one |
| Domperidone (TN) |
| Prestwick-06G02 |
| 5-Chloro-1-(1-(3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl)piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one maleate |
| Domperidone Maleate |
